

**The listing of claims presented below replaces all prior versions and listings of claims in the application.**

## **Listing of Claims**

Claims 1-71 (Cancelled)

72. (Currently amended) A drug delivery system consisting of:

- a) a continuous hydrophobic gelled non-polymeric matrix, ~~wherein the hydrophobic matrix is formed by gelling action of an emulsifier dissolved in an oily phase;~~
- b) a discontinuous phase consisting of a polymer dissolved in a water soluble organic solvent and
- c) a biologically active or inactive agent dispersed within the discontinuous phase;- wherein said drug delivery system is in the form of gelled droplet in oil dispersion.

73. (Currently Amended) The drug delivery system of claim 72, wherein the gelled droplet in oil dispersion forms microparticles *in-situ*, when the discontinuous phase comes in contact with any aqueous medium present inside a body.

74. (Previously presented) The drug delivery system of claim 72, wherein the discontinuous phase, comprises a biodegradable polymer.

75. (Previously presented) The drug delivery system of claim 74, wherein the biodegradable polymer is selected from the group consisting of polylactides, polyglycolides, poly lactics, polylactic acid-co-glycolic acid, polylactide-co-glycolides, polyesteramides, star-branched polymers, polyphosphoesters, albumin, fibrin, fibrinogen combinations, polycaprolactones, polydioxanones, polycarbonates, polyhydroxybutyrates, polyalkylene oxalates, polyanhydrides, polyamides, polyurethanes, polyacetals, polyketals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, poly(malic acid), poly(amino acids), chitin, chitosan, polyorthoesters, gelatin, collagen, polyethylene glycols, polyethylene oxides, polypropylene oxides, polyethers, betacyclodextrin, polysaccharides, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl-

alcohol, polyoxyethylene-polypropylene block copolymers; and copolymers, terpolymers and combinations and mixtures thereof.

76. (Currently amended) The drug delivery system of claim 72, wherein the discontinuous phase comprises a solvent for a polymer that is selected from the group consisting of N-methyl-2-pyrrolidone, N,N'-dimethylacetamide, water, 2-pyrrolidone, sorbitol, dimethyl sulfoxide, dimethylformamide, glycofural, glycerolformal, propylene glycol, ~~polyethylene glycol~~, glycerol, caprolactam, decylmethyl sulfoxide, ethanol, dialkylamides, combinations and mixtures thereof.

Claims 77 to 81 (Cancelled)

82. (Currently amended) The drug delivery system of claim 72, wherein the biologically active agent is selected from the group consisting of peptide drugs, protein drugs, desensitizing agents, antigens, ~~vaccines~~, anti-infectives, antibiotics, antimicrobials, antineoplastics, antitumor, antiallergenics, steroidal anti-inflammatory agents, analgesics, decongestants, miotics, anticholinergics, sympathomimetics, sedatives, hypnotics, antipsychotics, psychic energizers, tranquilizers, androgenic steroids, estrogens, progestational agents, humoral agents, prostaglandins, analgesics, antispasmodics, antimalarials, antihistamines, cardioactive agents, non-steroidal anti-inflammatory agents, antiparkinsonian agents, antihypertensive agents, beta-adrenergic blocking agents, nutritional agents, antivirals, DNA fragments, nucleic acids, RNA fragments, oligonucleotides, radioisotopes, or combinations of these classes of compounds or other forms such as uncharged molecules, molecular complexes, salts, ethers, esters, amides, and other chemically modified forms of the biologically active agent which are biologically activated when injected into a body.

83. (Previously presented) The drug delivery system of claim 72, wherein the biologically active agent is selected from the group consisting of leuprolide acetate, goserelin acetate, octreotide acetate, paclitaxel, chlorpheniramine maleate, trimethoprim, sulfamethoxazole, pseudoephedrine hydrochloride, olanzapine, captopril, lidocaine hydrochloride, felodipine, indomethacin, povidone iodine and terbutaline sulfate.

Claims 84 to 95 (Cancelled)

96. (Currently amended) The drug delivery system of claim 72 wherein the biologically active agent is mainly released by formation of polymeric microparticles and degradation of the polymer.

97. (Currently amended) The drug delivery system of claim 72 wherein the biologically active agent is additionally released by its dissolution into the oily continuous phase and then by further partitioning into an aqueous medium present inside a body.

Claims 98 and 99 (Cancelled).

100. (Withdrawn) A method for treating prostate cancer comprising administering to a subject in need thereof the drug delivery according to claim 83 wherein the biologically active agent is leuprolide acetate.

101. (Withdrawn) A method for treating breast cancer comprising administering to a subject in need thereof the drug delivery according to claim 83 wherein the biologically active agent is paclitaxel.

102. (Cancelled)